US prescription peptides: data for reporters
HHS published its peptide policy in the Federal Register on October 30, 2026. It lets US 503A pharmacies compound 6 peptides for a named patient with a prescription. We checked 250 US sellers of those peptides against public evidence. The data is free to use with credit.
250
sellers checked
174
ranked
11
no prescription check
10
name no pharmacy
What we found
- 11 US-facing sellers have no prescription check. 10 sell the peptides as “research use only” and 2 take card payment before any medical question. See the list and sources.
- We re-checked their home pages on October 30, 2026, the day the policy was published. All 10 sellers with research-use wording still list covered peptides with that wording.
- Of the 174 ranked pharmacies and clinics, 4 have a pharmacy licence we could confirm on a state board website. A low score means missing proof, not wrongdoing.
- On October 30, 2026 we searched the whole site of the 12 clinics whose pharmacy was unknown. 10 name no pharmacy anywhere public.
- 65 more sellers were checked but not ranked. Each has the reason on its page. See the full list.
About the data
- The CSV has one row per seller: our checks, the result, the detail and the source page for each.
- We use public pages, state pharmacy boards, the NPI registry and FDA warning letters. We stopped before payment and did not buy.
- How we score: methodology. The policy: Federal Register 2026-22192, docket HHS-OASH-2026-0496.
- Credit: “Peptide Scanner (peptidescanner.co)”. Please link to the page you use.
- Sellers can send evidence and we will re-check. Right of reply.
Contact
Sam Human, Co-founder, Peptide Scanner. media@peptidescanner.co. More about us in the Media Center.